Earlier this week, San Diego Startup Galant announced a $ 18 million in funding to bring the first FDA approved ready-to-use stem cell therapy in veterinary. If this regulator passes the muster, it can create a new way to treat our fur children.
It is still an experimental field, even though people have been researching stem cells for humans for decades. The first goal of the seven-year-year galvanant is a painful mouth condition in cats that are called Felin Chronic Gingvostomatitis (FCGS), which Galant says FDA approval in early 2026 may be approved.
The region has shown some encouraging results. Study on arthritis dogs showed improvement in pain and mobility, with some benefits lasting two years. But when researchers tried uniform treatment for kidney disease in cats – this is another condition that wanted to deal with galvanant – the results were more mixed.
The convenience of the gallant makes the approach different. Most stem cell remedies today require patients with matching tissue to patients or donors, while the medical donor of the gallant uses-to-use cells prepared from animals, even if they are a separate species.
Investors clearly see possible here. The funding round was led by the current Backer Digitalis Ventures, with the participation of the Novakvest Capital Management, which first invested in the first FDA approved human stem cell therapy.
The company has an interesting backstory. The founder of Galant, Aaron Hirshorn first sold his biggest opponent to Dogwake at Dog-Sitting Marketplace, Rover. Hirshorn died in 2021; Galant is now led under the leadership of Linda Black, who almost joined its Chairman and Chief Scientific Officer from the beginning. Galant has now raised at least $ 44 million from investors.
